- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: AlahmadyHamad Elsamman EGYPT
Back to previous
To assess the efficacy and safety of cilary sulcus implantation of a foldable IOL in correction of pseudophakic ametropia.
: Ophthalmology department, faculty of medicine , Sohag university, Egyot
This prospective non randomized study included 10 eyes of 10 patients with post-phacoemulsification ammetropia. Included in this study were patients with previous phacoemulsification with in-bag IOL implantation with postoperative spherical error. Before surgery, all patients were subjected to complete ophthalmic examination include uncorrected (UCVA) and best distance corrected (BDCVA) visual acuity, intraocular pressure (IOP) measurement and fundus examination. The power of the secondary IOL was determined using Haigis formula based on anterior chamber depth (ACD) and effective lens power. The secondary IOL used in the study was a multipiece foldable designed for sulcus fixation.
The median age of the ten patients (6 men and 4 women) was 51.53 years (38-75 years). The mean follow-up was 8 months. The mean spherical equivalent decreased from -1.25 D ± 0.75 (SD) (-4.00 to +3.00 D) preoperatively to -0.25 ± 0.40 D (-0.50 to +0.25 D) postoperatively. All patients had improved UDVA postoperatively; the mean Landolt,s UDVA 1 month postoperatively was 0.9 ± 0.1, which remained stable throughout the study. Three eyes (33.3%) had a neodymium:YAG laser capsulotomy before secondary IOL implantation. All surgeries were uneventful. One eye (10%) had an IOP increase to 28 mmHg on the first postoperative day. No signs of pigment dispersion, iris bulging, foreign-body giant cell formation were observed during the follow-up. Decentration of the secondary IOL occurred in 1 eye (10%).
this pilot study found that implantation of a secondary IOL in the ciliary sulcus was safe, causing less trauma to surrounding tissues than would occur after IOL exchange. Follow-up examinations to date have found no complications. FINANCIAL INTEREST: NONE